FMP

FMP

Enter

LXRX - Lexicon Pharmaceutic...

Financial Statements of Lexicon Pharmaceuticals, Inc.(LXRX), Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, a

photo-url-https://financialmodelingprep.com/image-stock/LXRX.png

Lexicon Pharmaceuticals, Inc.

LXRX

NASDAQ

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

1.65 USD

0.02 (1.21%)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep